文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

欧洲实施药物基因组学的策略:U-PGx联盟设计与实施

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.
PubMed 文献 · Clin Pharmacol Ther · 2017-01-01

药物基因组学(PGx)临床应用仍有限,现有证据多限于特定药物-基因对,缺乏将PGx标记物组合纳入常规诊疗的集体临床效用证据。U-PGx联盟(欧盟Horizon-2020资助)旨在通过前瞻性、区组随机对照研究PREPARE,在七个欧洲国家医疗体系中实施预emptive PGx标记物组合检测,评估对患者结局和成本效果的影响。该计划具有多中心、多基因、多药物、多族裔和多医疗体系的特点。

要点

  • U-PGx联盟由欧盟Horizon-2020资助,旨在推动PGx标记物组合的常规临床应用。
  • PREPARE研究为前瞻性、区组随机对照设计,在七个欧洲国家实施预emptive基因分型。
  • 研究将评估PGx组合检测对患者结局和成本效果的影响,填补集体临床效用证据空白。

核心结论

  • U-PGx联盟通过PREPARE研究评估将PGx标记物组合预emptive检测纳入常规医疗对患者结局和成本效果的影响。

研究设计与样本

  • PREPARE为前瞻性、区组随机对照临床研究,在七个欧洲国家的医疗体系中实施预emptive PGx标记物组合基因分型。

主要发现

  • 当前PGx实施研究虽已启动,但将PGx标记物组合纳入常规诊疗的集体临床效用尚未确定,证据基础仍限于特定药物-基因对。

关键数值与推荐

  • PREPARE检测的PGx标记物组合为已有指南可用的临床相关标记物。

临床怎么用

  • 临床可参考U-PGx模式,对已有指南的PGx标记物开展预emptive组合检测,并同步评估患者结局与成本效果。

局限性

  • 目前将PGx标记物组合纳入常规诊疗的集体临床效用证据有限,主要基于特定药物-基因对。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the European Commission's Horizon-2020 program, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi-ethnic, and multihealthcare system approach.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. van der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther. 2017. PMID: 28027596. doi:10.1002/cpt.602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。